Vicore Pharma Holding AB (VICOR)

Stockholm
Currency in SEK
8.540
-0.010(-0.12%)
Closed·
VICOR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VICOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.3808.580
52 wk Range
6.09023.449
Key Statistics
Edit
Prev. Close
8.55
Open
8.52
Day's Range
8.38-8.58
52 wk Range
6.09-23.449
Volume
274.98K
Average Volume (3m)
386.76K
1-Year Change
-55.44%
Book Value / Share
4.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VICOR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.521
Upside
+269.10%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
No news in this category
Looks like there are no results in this news category

Vicore Pharma Holding AB Company Profile

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Compare VICOR to Peers and Sector

Metrics to compare
VICOR
Peers
Sector
Relationship
P/E Ratio
−6.3x−8.3x−0.5x
PEG Ratio
−0.71−0.200.00
Price/Book
1.9x7.0x2.6x
Price / LTM Sales
329.5x21.5x2.9x
Upside (Analyst Target)
321.8%97.8%45.8%
Fair Value Upside
Unlock11.1%8.6%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 31.521
(+269.10% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.44 / -0.371
Revenue / Forecast
900.00K / --
EPS Revisions
Last 90 days

People Also Watch

25.2000
ATIC
+6.78%
1,760.00
MANGS
+1.15%
39.95
NELLY
-0.25%
45.20
DEDIC
+4.15%
5.90
TRAD
-2.64%

FAQ

What Is the Vicore Pharma Holding AB (VICOR) Stock Price Today?

The Vicore Pharma Holding AB stock price today is 8.54

What Stock Exchange Does Vicore Pharma Holding AB Trade On?

Vicore Pharma Holding AB is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Vicore Pharma Holding AB?

The stock symbol for Vicore Pharma Holding AB is "VICOR."

What Is the Vicore Pharma Holding AB Market Cap?

As of today, Vicore Pharma Holding AB market cap is 2.01B.

What Is Vicore Pharma Holding AB's Earnings Per Share (TTM)?

The Vicore Pharma Holding AB EPS (TTM) is -1.86.

When Is the Next Vicore Pharma Holding AB Earnings Date?

Vicore Pharma Holding AB will release its next earnings report on 21 Aug 2025.

From a Technical Analysis Perspective, Is VICOR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.